Abstract
In recent years, drug delivery systems are especially interesting because they allow therapeutic efficiency and reduce side effects. Conjugates of hyaluronic acid and chemotherapeutic agents, especially taxol, have been recognized as excellent solution for many therapeutic indications. The aim of conjugation of taxol with hyaluronic acid was the toxicity reduction on healthy cells and increase of selectivity on tumor cells. Hyaluronic acid could be used in various pharmaceutical preparations, also in parenteral, because of its biocompatibility and biodegradability. Hyaluronic acid as a carrier belongs to in situ gelling systems, which is passing a phase transition in response to external conditions such as temperature, different pH value or the presence of ions, enabling prolonged effect of the drug substances. Many tumor cells have a large number of receptors for hyaluronic acid, which has a great affinity for the tumor cells. The incorporation of taxol in gelling system of hyaluronic acid provides sustained drug release, increased anticancer activity, reduced damage of healthy cells and increased selectivity on cancer cells.
Keywords: taxol, hyaluronic acid, in situ systems, drug delivery
How to Cite:
Ćujić, N., Ibrić, S., Bigović, D., Noveski, N. & Šavikin, K., (2015) “PHARAMACEUTICAL HYALURONIC ACID BASED CARRIERS FOR PARENTERAL USE, PARTICULARLY CONJUGATES WITH TAXOL: A REVIEW”, Lekovite Sirovine 35(1), 75-87. doi: https://doi.org/10.5937/leksir1535075c
Rights:
Authors retain the copyright of the published article
Downloads:
Download PDF
View PDF
5 Views
2 Downloads